deltatrials

Rheumatoid arthritis Trials in Whittier, United States

Conditions / Rheumatoid arthritis / Whittier, United States

Clinical trials for Rheumatoid arthritis investigate a range of treatment strategies and patient populations.

43 total trials for this combination

Showing top 10 of 43 trials

Trials

NCT ID Title Status Phase
NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis COMPLETED PHASE3
NCT00717236 Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis COMPLETED PHASE3
NCT01202773 A Study in Participants With Rheumatoid Arthritis TERMINATED PHASE3
NCT01331837 A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors COMPLETED PHASE4
NCT03915964 A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis COMPLETED PHASE4
NCT02706847 A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs COMPLETED PHASE3
NCT00443443 A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE) COMPLETED
NCT02629159 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate ACTIVE_NOT_RECRUITING PHASE3
NCT00891020 A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs) COMPLETED PHASE3
NCT01283971 A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor TERMINATED PHASE4

Related Pages